Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
429 people get RDY articles and Market Currents by email alert.
Get email alerts on RDY »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
Dr. Reddy's And Pfizer Finally Settle Lipitor DisputeZacks Investment Research • Thu, Sep 1, 2011 -
-
-
-
-
-
-
-
Dr. Reddy's Posts Big Earnings Beat on Nausea Treatment SalesSA Editor Eli Hoffmann • Fri, May 18, 2007 -
Dr. Reddy's Launches Generic ZofranAaron F. Barkoff • Wed, Jan 24, 2007 -
Indian Market Report: Dr. Reddy's Moving Up QuietlyDinesh Pandya • Mon, Dec 25, 2006
-
Reddy's is Ready for Aggressive GrowthHari Vepadharmalingam • Tue, Sep 5, 2006 -
Indian Pharma Companies: No Respite Yet (RDY, RBXLF)Wisdomsmith • Wed, Jan 25, 2006
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
Mylan: Profit From The Generics Boom With This PharmaCris Frangold • Thu, Nov 8, 2012 -
-
Analyst Scott Power Finds The Upside In Biotech Down UnderLife Sciences Report • Thu, Nov 8, 2012 -
-
-
-
-
-
-
India Markets Friday Wrap-Up: Persistent Selling Mars Indian IndicesEquitymaster • Fri, Jul 20, 2012
-
India Markets Wednesday Wrap-Up: Late Buying Fuels Indian IndicesEquitymaster • Wed, Jul 18, 2012
-
India Markets Monday Wrap-Up: Global Signals Lead To Sell-OffEquitymaster • Mon, Jul 9, 2012
-
-
High Flying Indian ADRs: Play A Turnaround In IndiaQineqt • Mon, Jul 2, 2012 -
India Markets Monday Wrap-Up: Volatility Plagues Indian IndicesEquitymaster • Mon, Jul 2, 2012
-
India Markets Monday Wrap-Up: Persistent Selling Mars IndicesEquitymaster • Mon, Jun 18, 2012
-
Dr. Reddy's And Merck Serono Partner On BiosimilarsThe Burrill Report • Sun, Jun 10, 2012
-
Business Wire (Jun 3, 2013)
-
at CNBC.com (May 14, 2013)
-
Business Wire (Feb 14, 2013)
-
Business Wire (Oct 10, 2012)
-
at CNBC.com (Oct 8, 2012)
-
Business Wire (Oct 8, 2012)
-
at MarketWatch.com (May 18, 2012)
-
Business Wire (Apr 19, 2012)
-
Business Wire (Jan 16, 2012)
-
at MarketWatch.com (Jul 15, 2011)
-
at MarketWatch.com (Mar 10, 2011)
-
at CNBC.com (Feb 17, 2011)
-
at CNBC.com (Feb 1, 2011)
-
at MarketWatch.com (Jan 19, 2011)
-
at CNBC.com (Jan 11, 2011)
-
at MarketWatch.com (Dec 22, 2010)
-
at MarketWatch.com (Nov 18, 2010)
-
at CNBC.com (Nov 8, 2010)
-
at MarketWatch.com (Jun 15, 2010)
RDY vs. ETF Alternatives
Company Description
Dr. Reddy’s Laboratories Limited (“DRL” or the “parent company”), together with its subsidiaries (collectively, the “Company”), is a leading India-based pharmaceutical company headquartered in Hyderabad, Andhra Pradesh, India. The Company’s principal areas of operation are in pharmaceutical... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, May 11, 2012, 7:28 AM Dr. Reddy's Laboratories (RDY): FQ4 EPS of $0.40 in-line. Revenue of $522M (+32% Y/Y) beats by $126M. (PR) Comment! [Earnings, Healthcare]
-
Michael Bryant
Watson Pharma (ACT) may be the best generic drug stock besides Teva Pharma (TEVA), Taro Pharma (TARO), and Indian maker Dr. Reddies (RDY). - View all 0 replies
-
freefdawatchlist
http://stks.co/3lxm Tomorrow premarket earning $RDY, $NVDA, SOL, $RNF, URRE, CBMX, AMOT, ALIM - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Michael Bryant
"Big Pharma Vies For India's $12 Billion Drug Market." Dr. Reddy's Laboratories (RDY) is a win-win. http://bloom.bg/nz2VdU - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Michael Bryant
Hey, I heard "smart money" is moving into India. Maybe you should, too. My favorite Indian stocks are TTM, RDY, and IBN. - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES